Detalhe da pesquisa
1.
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
BMC Cancer
; 21(1): 1162, 2021 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715804
2.
Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
BMC Med Res Methodol
; 21(1): 282, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922454
3.
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
BMC Cancer
; 20(1): 304, 2020 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32293341
4.
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
JAMA Oncol
; 8(4): 597-606, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201264
5.
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
JAMA Netw Open
; 5(2): e2145460, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35226087
6.
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35758620
7.
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Curr Oncol
; 29(3): 2046-2063, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323365
8.
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
JAMA Netw Open
; 5(8): e2225118, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917122
9.
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Curr Oncol
; 28(5): 4174-4183, 2021 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34677272
10.
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Curr Oncol
; 28(6): 4645-4654, 2021 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34898572
11.
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma.
Leuk Lymphoma
; 61(5): 1097-1107, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31931647
12.
Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
CMAJ Open
; 8(4): E772-E778, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33234584
13.
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Cancer Med
; 9(1): 160-169, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724340
14.
Reply to C.G. Azzoli et al and C. Chouaid et al.
J Clin Oncol
; 32(31): 3578-9, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25199757